Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Jun;476(6):2439-2447.
doi: 10.1007/s11010-021-04097-2. Epub 2021 Feb 18.

Association of macrophage inhibitory factor -1 polymorphisms with antiviral efficacy of type 1b chronic hepatitis C

Songdao Ye  1 , Yao Chen  2 , Xiaoting Lou  3 , Xuanmei Ye  1 , Xunjun Yang  4   5
Affiliations
Clinical Trial

Association of macrophage inhibitory factor -1 polymorphisms with antiviral efficacy of type 1b chronic hepatitis C

Songdao Ye et al. Mol Cell Biochem. 2021 Jun.

Abstract

The expression of macrophage inhibitory factor-1 (MIC-1) increases in patients with chronic hepatitis C (CHC), but whether MIC-1 level and its polymorphism affect the antiviral efficacy of CHC has not yet been reported. The present study aimed to investigate the association between MIC-1 polymorphism and antiviral efficacy in patients with CHC genotype 1b (CHC 1b). A total of 171 patients with CHC1b were recruited. The polymorphisms of rs1059369 and rs1059519 in MIC-1 were detected by DNA sequencing. All patients received a standard dose of polyethylene glycol interferon + ribavirin (PR regimen), and divided into response, nonresponse, sustained virological response (SVR), and non-sustained virological response (NSVR) groups based on HCV RNA levels. The genotype distribution of the two single nucleotide polymorphisms (SNPs) did not differ between the response and nonresponse groups, SVR and non-SVR groups. However, the level of MIC-1 was positively correlated with ALT, AST, PIIINP, CIV, and HCV RNA (P < 0.05). Compared to before treatment, the level of MIC-1 in plasma was significantly decrease in the response group but not in the non-responsive group. Our results suggest that the level of MIC-1 in CHC1b is correlated with liver cell injury, liver fibrosis index, and viral load. However, the polymorphism of rs1059369 and rs1059519 may have negligible impact in expression of MIC-1 and efficacy of antiviral therapy in CHC patient.

Keywords: Antiviral therapy; Chronic hepatitis C; Macrophage inhibitory factor-1; Single nucleotide polymorphisms.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Fig. 1
Fig. 1
Comparison of CHC 1b patients before and after treatment of plasma MIC-1. The level of MIC-1 in the response group was significantly different between after treatment and before treatment (P = 0.04). Similarly, significant difference was observed in the MIC-1 between the response and nonresponse groups after treatment (P = 0.002)
Fig. 2
Fig. 2
mic-1 polymorphism sequence. The arrow point indicates the corresponding SNP rs1059519[C/G] and rs1059369[A/T]
Fig. 3
Fig. 3
rs1059369 genotypes based levels of MIC-1 in CHC 1b patients before and after treatmentNo significant difference was detected in the MIC-1 level among different genotypes of rs1059369 in before or after treatment
Fig. 4
Fig. 4
rs1059519 genotypes based levels of MIC-1 in CHC 1b patients before and after treatmentNo significant difference was detected in the MIC-1 level among different genotypes of rs1059519 in before or after treatment
See this image and copyright information in PMC

References

    1. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45–57. doi: 10.1016/j.jhep.2014.07.027. - DOI - PubMed
    1. Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seropreValence. J Hepatol. 2013;57(4):1333–1342. doi: 10.1002/hep.26141. - DOI - PubMed
    1. Lemoine M, Nayagam S, Thursz M. Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. Future Virol. 2013;8:371–380. doi: 10.2217/fvl.13.11. - DOI - PMC - PubMed
    1. Chinese Society of Hepatology Chinese Society of Infectious Diseases, guidelines for the prevention and treatment of Hepatitis C (2015 update) Chin J Liver Dis. 2015;3:906–923. - PubMed
    1. WHO. Guidelines for the screening, care and treatment of persons with hepatitis C infection EB/OL. 2014-04 http://www.Who.Int/hepatitis/publications/hepatitis-c-guidelines/en/ - PubMed

Publication types

Substances

LinkOut - more resources